E.i. Dupont De Nemours and Company

Cytocure LLC

Paul J Durda

Marcia J Stone

Elliott D Kieff

Dennis E Vaccaro

William Robert Kenealy

Carolyn C Compton

James T Kurnick

Stephen R Petteway

Harvey Rabin

Gary Richard Pearson

Marcia Delaney Sullivan

David J Green

Ian S Dunn

This disclosure concerns an assay for detecting and/or quantifying a mammalian IgA antibody response to EBV-MA with an immobilized EBV-MA gp 350/220 lacking the transmembrane anchor domain.

Assay for detection and/or quantifying a mammalian IgA antibody response

A chemically synthesized 15 amino acid peptide designated peptide 1-69, which has the sequence of amino acids numbers 308 to 322 (RIQRGPGRAFVTIGK) of the human immunodeficiency virus-1 (HIV-1) IIIB env-coded protein, was used to immunize animals. Peptide 1-69 elicited in immunized animals antibodies that block HIV proliferation and block HIV-induced cell fusion in cell culture.

Human immunodeficiency virus (hiv) env-coded peptide capable of

A method for distinguishing between carcinomatous and/or precarcinomatous colo-rectal disease and histologically similar conditions due to diseases that are not carcinomatous or precarcinomatous comprising contacting colo-rectal tissue with an antibody that binds to blood group substance H and determining the presence of carcinomatous or precarcinomatous disease upon a finding of bound antibody, or the absence of such disease upon the finding of no bound antibody.

Method for detecting carcinomatous and precarcinomatous colo-rectal

A monoclonal hybridoma antibody with specificity for an antigen that is present on tumors of epithelial origin; the cell line secreting said antibodies; a process for selecting the cell line; a diagnostic process for detecting the antigen and a therapeutic process for neutrailization of the angtigen.

Monoclonal hybridoma antibody specific for a human epithelial antigen

Growing community of inventors

Needham, MA, United States of America

Paul J Durda